Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Evaluation of an online biomass probe to monitor cell growth and cell death.

Perani A, Gloria B, Wang D, Buffier AS, Berteau O, Esteban G, Smyth FE, Scott AM.

BMC Proc. 2011 Nov 22;5 Suppl 8:P16. doi: 10.1186/1753-6561-5-S8-P16. eCollection 2011. No abstract available.

2.

Impact on product quality of high productive GS-CHO cell lines.

Perani A, Gloria B, Wang D, Murphy R, Singh HK, Smyth FE, Scott AM.

BMC Proc. 2011 Nov 22;5 Suppl 8:P17. doi: 10.1186/1753-6561-5-S8-P17. eCollection 2011. No abstract available.

3.

MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.

Johns TG, McKay MJ, Cvrljevic AN, Gan HK, Taylor C, Xu H, Smyth FE, Scott AM.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):572-8. doi: 10.1016/j.ijrobp.2010.03.027. Epub 2010 Jul 16.

PMID:
20638193
4.

Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.

Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, Rigopoulos A, Smyth FE, Johns TG, Govindan SV, Goldenberg DM, Old LJ, Scott AM.

J Nucl Med. 2010 Jun;51(6):967-72. doi: 10.2967/jnumed.109.068395. Epub 2010 May 19.

5.

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.

Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA, Gambell P, Harrison S, Scott AM, Smyth FE, Darcy PK, Tainton K, Neeson P, Ritchie DS, Hönemann D.

Gene Ther. 2010 May;17(5):678-86. doi: 10.1038/gt.2010.21. Epub 2010 Mar 4.

PMID:
20200563
6.

Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.

Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM.

Clin Cancer Res. 2009 Nov 1;15(21):6709-15. doi: 10.1158/1078-0432.CCR-09-0536. Epub 2009 Oct 13.

7.

Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM.

Prostate. 2009 Jan 1;69(1):92-104. doi: 10.1002/pros.20856.

8.

Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.

Kelly MP, Lee FT, Tahtis K, Power BE, Smyth FE, Brechbiel MW, Hudson PJ, Scott AM.

Cancer Biother Radiopharm. 2008 Aug;23(4):411-23. doi: 10.1089/cbr.2007.0450.

9.

Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.

Westwood JA, Murray WK, Trivett M, Shin A, Neeson P, MacGregor DP, Haynes NM, Trapani JA, Mayura-Guru P, Fox S, Peinert S, Honemann D, Prince HM, Ritchie D, Scott AM, Smyth FE, Smyth MJ, Darcy PK, Kershaw MH.

Gene Ther. 2008 Jul;15(14):1056-66. doi: 10.1038/gt.2008.47. Epub 2008 Mar 27.

PMID:
18369322
10.
11.

A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.

Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, Hoffman EW, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:14.

12.

A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.

Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ.

Clin Cancer Res. 2007 Jun 1;13(11):3286-92.

13.

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. Epub 2007 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15965. Ritter, Gerd [added].

15.

Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, Smyth FE, Cartwright GA, Power BE, Hönemann D, Prince HM, Darcy PK, Kershaw MH.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19051-6. Epub 2005 Dec 19.

16.

Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.

Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, Smyth FE, Brechbiel MW, Nice EC, Burgess AW, Scott AM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7080s-7086s.

17.

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM.

Clin Cancer Res. 2005 Jul 1;11(13):4818-26.

18.

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.

Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, U P, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ.

Clin Cancer Res. 2005 Jul 1;11(13):4810-7.

19.

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.

Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM.

Br J Cancer. 2005 Mar 28;92(6):1069-77.

20.

Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.

Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, Smyth FE, Lee FT, Cebon J, Davis ID, Hopkins W, Mountain AJ, Rigopoulos A, Hanai N, Old LJ.

Cancer Immun. 2005 Feb 22;5:3.

21.

Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.

Liu Z, Panousis C, Smyth FE, Murphy R, Wirth V, Cartwright G, Johns TG, Scott AM.

Hybrid Hybridomics. 2003 Aug;22(4):219-28.

PMID:
14511567
22.

Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.

Tahtis K, Lee FT, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, Obata Y, Stockert E, Hall CM, Old LJ, Rettig WJ, Scott AM.

Mol Cancer Ther. 2003 Aug;2(8):729-37.

23.

Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.

Mitchell P, Lee FT, Hall C, Rigopoulos A, Smyth FE, Hekman AM, van Schijndel GM, Powles R, Brechbiel MW, Scott AM.

J Nucl Med. 2003 Jul;44(7):1105-12.

24.

Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.

Liu Z, Lee FT, Hanai N, Smyth FE, Burgess AW, Old LJ, Scott AM.

Cancer Immun. 2002 Oct 7;2:13.

25.

Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.

Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM.

Cancer Immunol Immunother. 2002 May;51(3):171-7. Epub 2002 Mar 1.

PMID:
11941456
26.

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM.

Int J Cancer. 2002 Mar 20;98(3):398-408.

27.

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ.

J Clin Oncol. 2001 Oct 1;19(19):3976-87.

PMID:
11579119
28.

Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector.

Power BE, Caine JM, Burns JE, Shapira DR, Hattarki MK, Tahtis K, Lee FT, Smyth FE, Scott AM, Kortt AA, Hudson PJ.

Cancer Immunol Immunother. 2001 Jul;50(5):241-50.

PMID:
11499807
29.

Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.

Lee FT, Rigopoulos A, Hall C, Clarke K, Cody SH, Smyth FE, Liu Z, Brechbiel MW, Hanai N, Nice EC, Catimel B, Burgess AW, Welt S, Ritter G, Old LJ, Scott AM.

Cancer Res. 2001 Jun 1;61(11):4474-82.

30.

Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.

Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, Smyth FE, Welt S, Old LJ, Scott AM.

J Nucl Med. 2001 May;42(5):764-9.

31.
32.
33.

In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.

Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM.

Cancer Res. 2000 Sep 1;60(17):4804-11.

34.

Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.

Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FJ, Harris WJ, Armour KL, Rood J, Kypridis A, Kronina V, Murphy R, Lee FT, Liu Z, Kitamura K, Ritter G, Laughton K, Hoffman E, Burgess AW, Old LJ.

Cancer Res. 2000 Jun 15;60(12):3254-61.

35.

Release of latent glucuronosyltransferase activity contributes to the sparing of glucuronidation in experimental liver injuries.

Desmond PV, Smyth FE, Mashford ML.

J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):350-4.

PMID:
7948817
36.

The ERGB/Fli-1 gene: isolation and characterization of a new member of the family of human ETS transcription factors.

Watson DK, Smyth FE, Thompson DM, Cheng JQ, Testa JR, Papas TS, Seth A.

Cell Growth Differ. 1992 Oct;3(10):705-13.

37.

Molecular organization and differential polyadenylation sites of the human ETS2 gene.

Watson DK, Mavrothalassitis GJ, Jorcyk CL, Smyth FE, Papas TS.

Oncogene. 1990 Oct;5(10):1521-7.

PMID:
2250910

Supplemental Content

Loading ...
Support Center